Omeros Corp. posted positive data for OMS721 in a well-established animal model of neovascular age-related macular degeneration (AMD). OMS721 is the company’s lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program. Omeros is currently completing a Phase I clinical trial of OMS721 in healthy subjects. The study was conducted by Dr. Puran S. Bora and colleagues at the Jones Eye Institute, Pat and Willard Walker Eye Research Center of the Un...